Two legitimate aims
The revised Common Rule and the 21st Century Cures Act arrived close together with partly conflicting aims. The Common Rule tightened consent expectations, including expectations for future research uses of biospecimens. The Cures Act promoted faster development and wider use of real-world evidence.
Both aims have a reasonable basis. Stronger consent protects autonomy by giving people more control over how their information or biological samples may be used. Faster evidence generation can help treatments reach patients sooner and can increase what researchers learn after a treatment enters routine care.
The tension is clearest when researchers want to use data or samples collected for another purpose. A person may have supplied information during ordinary medical care or provided a biospecimen for one research project without expecting every later question researchers might ask. A tighter consent standard can restrict those later uses. At the same time, a wider evidence agenda can increase the value of data and samples that were collected earlier.
For research conducted under the revised Common Rule, the practical issue is greater attention to consent for future research uses of biospecimens, with HHS documents in the Federal Register providing a source for the agency’s regulatory materials. For people whose information or samples are involved, this requires a closer review of whether their permission covers later work. The central question is how secondary uses can produce useful evidence without treating the original collection as unlimited permission.
Why real-world evidence is the pressure point
Real-world evidence raises the sharper issue because it relies on information generated outside controlled trial settings. The Cures Act’s support for wider use of this evidence, discussed in our analysis of the law’s expansion of real-world evidence, rests on its potential to speed development and inform regulatory decisions.
Routine clinical data can show what happens during ordinary care rather than only under a trial protocol. That makes the data useful for questions that are difficult to answer quickly in registration trials. The same data also raises questions about consent, data quality, and confounding.
Confounding matters because people who receive a treatment may differ from people who do not receive it in ways that also affect their outcomes. Trial designs are built to address that problem. Observational evidence is therefore useful, but it must be interpreted differently from evidence produced by a randomized trial.
Consent adds another issue. If data were collected for medical care or another purpose, using that information to study a new question may not fit neatly within the permission originally given. The more widely researchers seek to reuse information, the more directly that effort encounters the Common Rule’s concern with meaningful consent.
The evidence behind treatment claims
Much of what is known about these drugs outside registration trials comes from observational data, including claims analyses, registries, and post-marketing surveillance. That evidence can provide useful information about treatment in routine settings and can reveal patterns that registration trials may not fully capture.
It is also weaker than a randomized trial for some questions, especially long-term use, discontinuation, and weight regain. The trial evidence is thinnest in those areas. Observational findings may therefore help fill gaps, but they can also be overstated more easily.
Modern medication costs are part of the decision as well, and readers can review documented evidence in our GLP-1 comparison guide and KFF prescription drug research without treating price and evidence as the same question.
This distinction matters when a provider makes a confident claim about outcomes at two or five years. A claim based on routine-care data may provide useful information without establishing the same degree of certainty as a randomized trial. The source, design, and limits of the evidence should remain clear instead of being reduced to a simple promise.
A tradeoff that needs discipline
The two laws point in different directions because they address different risks. The revised Common Rule responds to the risk that people may lose control over future uses of their biospecimens. The Cures Act responds to the risk that slow or narrow evidence systems may delay useful knowledge and treatment development.
Neither concern disappears when the other receives attention. Faster evidence generation does not remove the need to consider consent. Stronger consent expectations do not eliminate the value of real-world evidence. The difficult task is to decide how secondary uses of data and samples can support useful research while respecting the limits of the original permission.
For readers assessing treatment claims, the practical lesson is to separate evidence types and match confidence to the study design behind them. Claims analyses, registries, and post-marketing surveillance can inform important questions, but they do not eliminate confounding or provide the certainty of a randomized trial. Our rankings stick to what is documented.